Literature DB >> 9640218

Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma.

L M Ellis1, Y Takahashi, C J Fenoglio, K R Cleary, C D Bucana, D B Evans.   

Abstract

Angiogenesis is essential for growth and metastasis of solid malignancies. In several tumours, tumour vessel count and expression of vascular endothelial growth factor (VEGF), a potent angiogenic factor, have been associated with prognosis. To determine if vessel count and VEGF expression are prognostic factors in pancreatic cancer, we examined these parameters in resected tumour specimens from 22 patients who did not receive pre-operative therapy. Paraffin-embedded tumour specimens were immunohistochemically stained for factor VIII (surrogate for vessels) and VEGF. Vessel counts and VEGF expression were evaluated without knowledge of patient outcome. The median follow-up for the entire group had not been reached as of 23.1 months (range 10-69 months). The mean vessel count and VEGF expression were no different between those patients who had recurrences and those who did not. By linear regression analysis, the correlation of VEGF expression with vessel count did not reach statistical significance (P = 0.0685). Survival and time to recurrence were similar in patients with high and low vessel counts and VEGF expression of 1, 2 or 3. Tumour differentiation or lymph node positivity had no effect on either VEGF expression or vessel count. Our data suggest that, in contrast to findings in other solid malignancies, vessel count and VEGF expression are not predictors of survival or recurrence in patients with resectable adenocarcinoma of the pancreas.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9640218     DOI: 10.1016/s0959-8049(97)10068-5

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  37 in total

1.  Suppression of vascular endothelial growth factor via siRNA interference modulates the biological behavior of human nasopharyngeal carcinoma cells.

Authors:  Hai B Zhou; Yi F Yin; Yan Hu; Xin Li; Li Y Zou; Yong J Li; Yu Gu; Bao Q Ou; Juan Fu; Jun H Du; Gang Wu
Journal:  Jpn J Radiol       Date:  2011-09-29       Impact factor: 2.374

2.  Impact of microvessel density on lymph node metastasis and survival after curative resection of pancreatic cancer.

Authors:  Christoph Benckert; Armin Thelen; Thorsten Cramer; Wilko Weichert; Gereon Gaebelein; Reinhard Gessner; Sven Jonas
Journal:  Surg Today       Date:  2011-11-10       Impact factor: 2.549

Review 3.  Clinical significance of vascular assessment by contrast-enhanced harmonic ultrasonography of pancreatic carcinomas.

Authors:  Masayuki Kitano
Journal:  J Gastroenterol       Date:  2005-06       Impact factor: 7.527

Review 4.  Antiangiogenic therapy in human gastrointestinal malignancies.

Authors:  J Heidemann; D G Binion; W Domschke; T Kucharzik
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

5.  Ductal adenocarcinoma of the pancreas: Expression of growth factor receptors, oncogenes and suppressor genes, and their relationship to pathological features, staging and survival.

Authors:  Antonio Lozano-Leon; Begona Vieites Perez-Quintela; Julio Iglesias-García; Jose Lariño-Noia; Evaristo Varo; Jeronimo Forteza; J Enrique Domínguez-Muñoz
Journal:  Oncol Lett       Date:  2010-11-23       Impact factor: 2.967

6.  Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis.

Authors:  Yong Gao; Zhiliang Jia; Xiangyu Kong; Qiang Li; David Z Chang; Daoyan Wei; Xiangdong Le; Huang Suyun; Shengdong Huang; Liwei Wang; Keping Xie
Journal:  Cancer Res       Date:  2011-06-14       Impact factor: 12.701

Review 7.  Clinical significance of angiogenesis in gastrointestinal cancers: a target for novel prognostic and therapeutic approaches.

Authors:  Ronnie Tung-Ping Poon; Sheung-Tat Fan; John Wong
Journal:  Ann Surg       Date:  2003-07       Impact factor: 12.969

8.  Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity.

Authors:  Zhiliang Jia; Yong Gao; Liwei Wang; Qiang Li; Jun Zhang; Xiangdong Le; Daoyan Wei; James C Yao; David Z Chang; Suyun Huang; Keping Xie
Journal:  Cancer Res       Date:  2010-01-19       Impact factor: 12.701

9.  A phase I surrogate endpoint study of SU6668 in patients with solid tumors.

Authors:  Henry Q Xiong; Roy Herbst; Silvana C Faria; Catherine Scholz; Darren Davis; Edward F Jackson; Timothy Madden; David McConkey; Marshall Hicks; Kenneth Hess; Chusilp Arthur Charnsangavej; James L Abbruzzese
Journal:  Invest New Drugs       Date:  2004-11       Impact factor: 3.850

10.  Tumor-specific expression of shVEGF and suicide gene as a novel strategy for esophageal cancer therapy.

Authors:  Ting Liu; Hai-Jun Wu; Yu Liang; Xu-Jun Liang; Hui-Chao Huang; Yan-Zhong Zhao; Qing-Chuan Liao; Ya-Qi Chen; Ai-Min Leng; Wei-Jian Yuan; Gui-Ying Zhang; Jie Peng; Yong-Heng Chen
Journal:  World J Gastroenterol       Date:  2016-06-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.